Stock events for Revvity, Inc. (RVTY)
Revvity's stock experienced several notable events in the past six months. In Q3 2025, the company reported earnings exceeding EPS expectations but slightly missing revenue projections and announced an agreement to acquire ACD/Labs. In December 2025, BofA Securities downgraded Revvity, and Goldman Sachs initiated coverage with a Neutral rating. In February 2026, Revvity announced Q4 and full-year 2025 financial results, exceeding market expectations, and unveiled Signals Xynthetica. The stock has shown negative returns recently due to cautious 2026 guidance and China market pressure.
Demand Seasonality affecting Revvity, Inc.’s stock price
Revvity experiences some demand seasonality, particularly in its instrument volumes between the third and fourth quarters, with the fourth quarter typically exhibiting seasonal strength. Despite these seasonal upticks, the company has faced ongoing reimbursement-related pressures in China Diagnostics and a cautious demand environment.
Overview of Revvity, Inc.’s business
Revvity, Inc. is a global life sciences and diagnostics company operating in the Healthcare sector, specifically within the Advanced Medical Equipment & Technology and Life Sciences Tools & Services industries. The company was rebranded from PerkinElmer in 2023, focusing on its life sciences and diagnostics businesses. Its Life Sciences segment offers technologies to aid researchers in understanding diseases and developing treatments, including reagents, assay kits, and imaging solutions. The Diagnostics segment focuses on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics, providing screening products for genetic disorders and infectious disease testing.
RVTY’s Geographic footprint
Revvity has a strong global presence, operating in over 160 countries with approximately 2,000 sales and service representatives across about 40 countries. Its major markets include the U.S., Europe, and China. Key operational hubs in the U.S. are Waltham, Hopkinton, and San Diego. In Europe, significant locations include Cambridge, Codolet, and Turku. Revvity also has active recruitment and operational hubs in cities like Krakow, Shanghai, and Mumbai.
RVTY Corporate Image Assessment
In the past year, Revvity's brand reputation has been generally associated with its diversified product portfolio, innovation leadership, and strong global presence. However, a Bretton Fund letter in March 2026 criticized Revvity's use of its COVID testing windfall, highlighting investor unease with management's capital allocation choices.
Ownership
Revvity's ownership is predominantly held by institutional investors, who collectively manage approximately 97.4% of shares. Key institutional shareholders include T. Rowe Price Investment Management, Inc., Vanguard Group Inc, and BlackRock, Inc. Alexis P. Michas is the largest individual shareholder, owning 0.60% of the company's stock.
